BerGenBio and Merck collaborate for BGB324 and Keytruda evaluation in NSCLC and TNBC

Biopharmaceutical firm BerGenBio has entered a collaborative agreement with Merck (MSD) to evaluate the combination of its BGB324 with Merck's Keytruda (pembrolizumab) to treat patients with advanced non-small-cell lung cancer (NSCLC) and triple-nega …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news